Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease

Cites (327)

Items 201–324 of 324

1. Iron Chelation Therapy for Malaria
   Mabeza, George F, Loyevsky, Mark, Gordeuk, Victor R, Weiss, Günter · 1999 · Pharmacology & Therapeutics
2. Chemical and Biological Considerations in the Treatment of Metal Intoxications by Chelating Agents
   Ole Andersen · 2004 · Mini-Reviews in Medicinal Chemistry
3. Vanadyl–biguanide complexes as potential synergistic insulin mimics
   Lenny Chick Ying Woo, Violet G. Yuen, Katherine H. Thompson, John Hugh McNeill, Chris Orvig · 1999 · Journal of Inorganic Biochemistry
4. Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
   Cappai, Roberto, Barnham, Kevin J. · 2008 · Neurochemical Research
5. β‐Amyloid protein oligomers induced by metal ions and acid pH are distinct from those generated by slow spontaneous ageing at neutral pH
   Genevieve M Klug, Dušan Lošić, Supundi, Supundi Subasinghe, Marie‐Isabel Aguilar, Lisandra L. Martin, David Henry Small · 2003 · European Journal of Biochemistry
6. Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease1
   John Savory, Mary M. Herman, Othman Ghribi · 2006 · Journal of Alzheimer s Disease
7. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease
   H. J. Stuerenburg · 2000 · Journal of Neural Transmission
8. Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions
   Des Raymond Richardson · 2004 · Annals of the New York Academy of Sciences
9. A novel approach to the identification and quantitative elemental analysis of amyloid deposits—Insights into the pathology of Alzheimer’s disease
   Reshmi Rajendran, Ren Minqin, Maria Dolores Ynsa, Gemma Casadesús, Mark A. Smith, George L. Perry, Barry B. Halliwell, F. Watt · 2009 · Biochemical and Biophysical Research Communications
10. The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease.
    V. Streltsov, S. J. Titmuss, V. Epa, K. Barnham, Colin L. Masters, J. Varghese · 2008 · Biophysical Journal
11. Chemical Stability of Nucleic Acid–Derived Drugs
    Dariusz Pogocki, Christian Schöneich · 2000 · Journal of Pharmaceutical Sciences
12. Delineating common molecular mechanisms in Alzheimer's and prion diseases
    Kevin Jeffrey Barnham, Roberto Cappai, Konrad T. Beyreuther, Colin Louis Masters, Andrew Francis Hill · 2006 · Trends in Biochemical Sciences
13. Effects of oral aluminum exposure on behavior and neurogenesis in a transgenic mouse model of Alzheimer's disease
    Diana Ribes, María Teresa Colomina, Paloma Vicens, José L. Domingo · 2008 · Experimental Neurology
14. Development of potential iron chelators for the treatment of Friedreich’s ataxia: ligands that mobilize mitochondrial iron
    Des Raymond Richardson, C. Mouralian, Prem Ponka, E. Becker · 2001 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
15. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial
    Marie José Kersten, Ruth L. Lange, Mathilde Smeets, Gerard Vreugdenhil, Klaas J. Roozendaal, W. Lameijer, Robert Goudsmit · 1996 · Annals of Hematology
16. Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia [see comments]
    VR Gordeuk, PE Thuma, GM Brittenham, Stenford Zulu, G Simwanza, A Mhangu, Gérard Flesch, Dean Parry · 1992 · Blood
17. Redox cycling of iron by Aβ42
    Ayesha Khan, Jon Dobson, Christopher Exley · 2005 · Free Radical Biology and Medicine
18. Genes associated with Parkinson syndrome
    Saskia Biskup, Manfred Gerlach, Andreas R. Kupsch, Heinz Reichmann, Peter Franz Riederer, P. Vieregge, Ullrich Wüllner, Thomas Gasser · 2008 · Journal of Neurology
19. ORAL ZINC IN WILSON'S DISEASE
    Tjaard Ubbo Hoogenraad, Cornelis J. A. Van den Hamer, R. Koevoet, E.G.W.M. de Ruyter Korver · 1978 · The Lancet
20. Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation
    Peter John Crouch, Deborah J. Tew, Tai Du, Diem Nguyen, Aphrodite Caragounis, Gulay Filiz, Rachel E. Blake, Ian Andrew Trounce, Cynthia P.W. Soon, Katrina M. Laughton et al. · 2009 · Journal of Neurochemistry
21. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease
    Ryong‐Woon Shin, Theo P.A. Kruck, Harunobu Murayama, Tetsuyuki Kitamoto · 2003 · Brain Research
22. Synthesis, Physicochemical Properties, and Biological Evaluation of Hydroxypyranones and Hydroxypyridinones: Novel Bidentate Ligands for Cell-Labeling
    Beverley L. Ellis, Anne‐Kathrin Duhme‐Klair, Robert C. Hider, M. Bilayet Hossain, S. K. RIZVI, Dick Van der Helm · 1996 · Journal of Medicinal Chemistry
23. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review
    George J. Kontoghiorghes · 1995 · The Analyst
24. N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells
    Johnny Amer, Daphné Atlas, Eitan Fibach · 2007 · Biochimica et Biophysica Acta (BBA) - General Subjects
25. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part II. Formation constants with iron(III) and iron(II)
    Lucia M. Wis Vitolo, Glenn T. Hefter, Brian W. Clare, John M. Webb · 1990 · Inorganica Chimica Acta
26. Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease
    Robert A. Cherny, Kevin Jeffrey Barnham, Toni Lynch, Irene Volitakis, Qiao-Xin Li, Catriona McLean, Gerd Multhaup, Konrad T. Beyreuther, Rudolph E. Tanzi, Colin Louis Masters et al. · 2000 · Journal of Structural Biology
27. Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity
    Tetsuhiro Niidome, Keita Takahashi, Yasuaki Goto, Saori Goh, Naoki Tanaka, Kaeko Kamei, Masatoshi Ichida, Saburo Hara, Akinori Akaike, Takeshi Kihara et al. · 2007 · Neuroreport
28. Pathogenic effects of α-synuclein aggregation
    Ditte M. S. Lundvig, Evo Lindersson, Poul Henning Jensen · 2004 · Molecular Brain Research
29. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY‐5Y cells
    Francisco Molina‐Holgado, Alessandra Gaeta, Paul T. Francis, Robert J. Williams, Robert C. Hider · 2008 · Journal of Neurochemistry
30. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate
    C. F. Mills, T.T. El-Gallad, Ian Bremner, G. Wenham · 1981 · Journal of Inorganic Biochemistry
31. 99m-Technetium carbohydrate conjugates as potential agents in molecular imaging
    Meryn L. Bowen, Chris Orvig · 2008 · Chemical Communications
32. The effect of aging on the mineral status of female mice
    Akemi Morita, Mieko Kimura, Yoshinori Itokawa · 1994 · Biological Trace Element Research
33. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone analogs
    E. Becker, Des Raymond Richardson · 1999 · Journal of Laboratory and Clinical Medicine
34. Vanadium Compounds in the Treatment of Diabetes
    Katherine H. Thompson, Chris Orvig · 2004 · Metal ions in biological systems
35. Chelate Mediated Transfer of Iron from Transferrin to Desferrioxamine
    Simeon Pollack, Philip Aisen, Fred D. Lasky, Grace A. Vanderhoff · 1976 · British Journal of Haematology
36. APP at a glance
    Michael S. Wolfe, Suzanne Y. Guénette · 2007 · Journal of Cell Science
37. Oxidative cleavage of vicinal diols: IBX can do what Dess–Martin periodinane (DMP) can
    Jarugu Narasimha Moorthy, Nidhi Singhal, Kalyan Senapati · 2007 · Organic & Biomolecular Chemistry
38. Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease
    Carlos Opazo, Sandra Luza, Victor L. Villemagne, Irene Volitakis, Christopher Cleon Rowe, Kevin Jeffrey Barnham, Dorothea Altschul, Colin Louis Masters, Robert A. Cherny, Ashley Ian Bush · 2006 · Aging Cell
39. Friedreich's Ataxia, No Changes in Mitochondrial Labile Iron in Human Lymphoblasts and Fibroblasts
    Sturm, Brigitte, Bistrich, Ute, Schranzhofer, Matthias, Sarsero, Joseph P., Rauen, Ursula, Scheiber-Mojdehkar, Barbara, de Groot, Herbert, Ioannou, Panos, Petrat, Frank · 2005 · Journal of Biological Chemistry
40. Copper binding to the Alzheimer’s disease amyloid precursor protein
    G.K.-W. Kong, Luke A. Miles, Gabriela A. N. Crespi, Craig J. Morton, Hooi Ling Ng, Kevin Jeffrey Barnham, William J. McKinstry, Roberto Cappai, Michael W. Parker · 2007 · European Biophysics Journal
41. Iron chelation using subcutaneous infusions of diethylene triamine penta‐acetic acid (DTPA)
    Martin J. Pippard, Malcolm Joseph Jackson, Kathy Hoffman, Mary Petrou, C. B. Modell · 1986 · Scandinavian Journal of Haematology
42. Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1Electronic supplementary information (ESI) available: experimental details for the preparation of all derivatives and biological assays. See http://www.rsc.org/suppdata/ob/b2/b212066f/
    Caridad I Fernández, Ofelia Nieto, José Angel Fontenla, Emilia Rivas, Maria L. DE CEBALLOS, Alfonso Fernández‐Mayoralas · 2003 · Organic & Biomolecular Chemistry
43. Lipophilic coordination compounds: aluminum, gallium, and indium complexes of 1-aryl-3-hydroxy-2-methyl-4-pyridinones
    Zaihui Zhang, Steven J. Rettig, Chris Orvig · 1991 · Inorganic Chemistry
44. Hohenheim Consensus Workshop: Copper
    K. Schümann, H.-G. Classen, H. H. Dieter, Jürgen S. König, Gerd Multhaup, Margarete Rükgauer, KH Summer, J. Bernhardt, H-K Biesalski · 2002 · European Journal of Clinical Nutrition
45. Age-Related Changes in the Concentrations of Major and Trace Elements in the Brain of Rats and Mice
    Sentaro Takahashi, I. Takahashi, Hidenori Sato, Yoshihisa Kubota, Shohei YOSHIDA, Y. Muramatsu · 2001 · Biological Trace Element Research
46. Friedreich ataxia?update on pathogenesis and possible therapies
    Max Voncken, Panos A. Ioannou, Martin Bruce Delatycki · 2004 · Neurogenetics
47. Potential wool growth inhibitors. Improved syntheses of mimosine and related 4(1H)-Pyridones
    RLN Harris · 1976 · Australian Journal of Chemistry
48. Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment
    Goncalves, Sergio, Paupe, Vincent, Dassa, Emmanuel P, Rustin, Pierre · 2008 · BMC Neurology
49. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease
    Timothy B. Chaston, Des Raymond Richardson · 2003 · JBIC Journal of Biological Inorganic Chemistry
50. Role of zinc in ALS
    Andrew Paul Smith, Nancy M. Lee · 2007 · Amyotrophic Lateral Sclerosis
51. Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools
    K. P. Hoyes, John B. Porter · 1993 · British Journal of Haematology
52. Brain copper, iron, magnesium, zinc, calcium, sulfur and phosphorus storage in Wilson's disease
    Gavino Faa, Mosè Lisci, Maria Pina Caria, Rossano Ambu, Raf Sciot, Valeria Marina Nurchi, Roberta Silvagni, Angelo Diaz, Guido Crisponi · 2001 · Journal of Trace Elements in Medicine and Biology
53. Drug Insight: antioxidant therapy in inherited ataxias
    Massimo Pandolfo · 2008 · Nature Clinical Practice Neurology
54. The effect of N-alkyl modification on the antimalarial activity of 3- hydroxypyridin-4-one oral iron chelators
    C Hershko, EN Theanacho, Dan T. Spira, HH Peter, Paul S. Dobbin, Robert C. Hider · 1991 · Blood
55. Molecular Shuttle Chelation: The Use of Ascorbate, Desferrioxamine and Feralex-G in Combination to Remove Nuclear Bound Aluminum
    Theo P.A. Kruck, Jian-Guo Cui, Maire E. Percy, Walter J. Lukiw · 2004 · Cellular and Molecular Neurobiology
56. Antidotal effects of dimercaptosuccinic acid
    Guang‐Sheng Ding, You-yi Liang · 1991 · Journal of Applied Toxicology
57. Monamine Oxidase Inhibitors
    Hubert H. Fernandez, Jack J. Chen · 2007 · Clinical Neuropharmacology
58. Kinetic analysis of β-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing
    Wen-Pin Hu, Guan‐Liang Chang, Shean-Jen Chen, Yu‐Min Kuo · 2006 · Journal of Neuroscience Methods
59. First human studies with a high-molecular-weight iron chelator
    Paul R. Dragsten, Philip E. Hallaway, Gregory J. Hanson, Arthur E. Berger, Bruce K. Bernard, Bo E. Hedlund · 2000 · Journal of Laboratory and Clinical Medicine
60. Crystal structure of the tris 1,2-dimethyl-3-hydroxy-4-pyridinone (DMHP) complex with the Fe(III) ion
    Eric T. Clarke, Arthur E. Martell, Joseph H. Reibenspies · 1992 · Inorganica Chimica Acta
61. Spontaneous Resolution: From Three-Dimensional Crystals to Two-Dimensional Magic Nanoclusters
    Meir Lahav, Leslie Leiserowitz · 1999 · Angewandte Chemie International Edition
62. The antimalarial effect of iron chelators: Studies in animal models and in humans with mild falciparum malaria
    Hershko, C., Gordeuk, V.R., Brittenham, G.M., Thuma, P.E., Theanacho, E.N., Spira, D.T., Hider, R.C., Peto, T.E.A. · 1992 · Journal of Inorganic Biochemistry
63. Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques
    Meredin Stoltenberg, Mikkel Bruhn, Christian Skou Søndergaard, Peter Doering, Mark J. West, Agnete Larsen, Juan Carlos Troncoso, Gorm Danscher · 2005 · Histochemistry and Cell Biology
64. Deferiprone therapy for transfusional iron overload
    A. Victorhoffbrand · 2005 · Best Practice & Research Clinical Haematology
65. The lipophilic metal chelators DP‐109 and DP‐460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis
    Petri, Susanne, Calingasan, Noel Y., Alsaied, Osama A., Wille, Elizabeth, Kiaei, Mahmoud, Friedman, Jonathan E., Baranova, Oxana, Chavez, Juan C., Beal, M. Flint · 2007 · Journal of Neurochemistry
66. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents
    Céline Deraeve, Marguerite Piti, Honor? Mazarguil, Bernard Meunier · 2007 · New Journal of Chemistry
67. Modifications of boronic ester pro-chelators triggered by hydrogen peroxide tune reactivity to inhibit metal-promoted oxidative stress
    Louise K. Charkoudian, David M. Pham, A.M. Kwon, Abbey D. Vangeloff, Katherine J. Franz · 2007 · Dalton Transactions
68. Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols
    Annita Kolnagou, Charalambos P Economides, Eleni Eracleous, George John Kontoghiorghes · 2008 · Hemoglobin
69. Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum
    Bruno Pradines · 2002 · Journal of Antimicrobial Chemotherapy
70. Basic 3-hydroxypyridin-4-ones: Potential antimalarial agents
    Lotfollah Saghaei, Zu Dong Liu, Robert C. Hider · 2007 · European Journal of Medicinal Chemistry
71. Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease
    Alberta Samuele, Anna Mangiagalli, Marie‐Thérèse Armentero, Roberto Fancellu, Eleonora Bazzini, Mariapia Vairetti, Andrea Ferrigno, Plinio Richelmi, Giuseppe Nappi, Fabio Blandini · 2005 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
72. Vanadyl−Thiazolidinedione Combination Agents for Diabetes Therapy
    Tim Storr, Devin Mitchell, Péter Buglyó, Katherine H. Thompson, Violet G. Yuen, John Hugh McNeill, Chris Orvig · 2002 · Bioconjugate Chemistry
73. Design, Properties, and Effective Use of the Oral Chelator L1 and Other
    G Kontoghiorghes · 1990 · Annals of the New York Academy of Sciences
74. Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review
    George J. Brewer, Sofia Diana Merajver · 2002 · Integrative Cancer Therapies
75. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β Levels: Resolubilization of amyloid-β with transition metal ion chelators
    Justin Fonte, Judith Miklossy, Craig Atwood, Ralph Nigel Martins · 2001 · Journal of Alzheimer s Disease
76. 4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonate: report on non-β-sheet conformers of Alzheimer's peptide β(1-40)
    H. Levine · 2002 · Archives of Biochemistry and Biophysics
77. The effect of diethyldithiocarbamate on brain uptake of cadmium*1
    Louis R. Cantilena · 1982 · Toxicology and Applied Pharmacology
78. Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels
    S Schäfer, Frank–Gerald Pajonk, Gerd Multhaup, Thomas A. Bayer · 2007 · Journal of Molecular Medicine
79. Pyridoxal Isonicotinoyl Hydrazone
    Gary M. Brittenham · 1990 · Annals of the New York Academy of Sciences
80. Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Aβ(1–42) toxicity
    Orit Bartov, Rukhsana Sultana A, David Allan Butterfield, Daphné Atlas · 2006 · Brain Research
81. Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer's therapy
    Tim Storr, Lauren E. Scott, Meryn L. Bowen, David E. Green, Katherine H. Thompson, Harvey J. Schugar, Chris Orvig · 2009 · Dalton Transactions
82. Antiparkinson Prodrugs
    Antonio Di Stefano, Piera Sozio, Laura Serafina Cerasa · 2008 · Molecules
83. Metal ion chelation in neurodegenerative disorders
    Itzchak Angel, Adina Bar, Tammy Horovitz, Galia Taler, Michael Krakovsky, Dalia Resnitsky, Gilad Rosenberg, Sarina Striem, Jonathan E. Friedman, Alex Kozak · 2002 · Drug Development Research
84. Therapeutic iron chelators and their potential side-effects
    S. Singh, Hh Khodr, M. I. Taylor, Robert C. Hider · 1995 · Biochemical Society Symposia
85. Mixed Hydroxypyridinonate Ligands as Iron Chelators1
    Seth M. Cohen, Brendon O'Sulliva, Kenneth N. Raymond · 2000 · Inorganic Chemistry
86. Phase Ib clinical trial of starch‐conjugated deferoxamine (40SD02): a novel long‐acting iron chelator
    Paul Harmatz, Robert W. Grady, Paul R. Dragsten, Elliott P. Vichinsky, Patricia J. Giardina, Jacqueline Madden, Michael Jeng, Becky Miller, Gregory Hanson, Bo E. Hedlund · 2007 · British Journal of Haematology
87. Carbohydrate-Bearing 3-Hydroxy-4-pyridinonato Complexes of Gallium(III) and Indium(III)
    David E. Green, Cara L. Ferreira, Robert V. Stick, Brian O. Patrick, Michael J. Adam, Chris Orvig · 2005 · Bioconjugate Chemistry
88. Protection against Hydrogen Peroxide-Mediated Cytotoxicity in Friedreich’s Ataxia Fibroblasts Using Novel Iron Chelators of the 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone Class
    Chai K. Lim, Danuta S. Kalinowski, Des Raymond Richardson · 2008 · Molecular Pharmacology
89. Synthesis and X-ray crystal structure of tris(1,2-dimethyl-3-hydroxypyrid-4-onato)iron(III)
    John Charalambous, Azita Dodd, Mary McPartlin, Simba O. C. Matondo, Navin D. Pathirana, Harold R. Powell · 1988 · Polyhedron
90. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells
    Paula M. B. Pahl, Marcus A. Horwitz, Kathryn B. Horwitz, Lawrence D. Horwitz · 2001 · Breast Cancer Research and Treatment
91. Withdrawal of penicillamine from zinc sulphate–penicillamine maintenance therapy in Wilson's disease: Promising, safe and cheap
    Sanjib Sinha, Arun B. Taly · 2007 · Journal of the Neurological Sciences
92. Altering pyridinone N-substituents to optimise activity as potential prodrugs for Alzheimer's disease
    Lauren E. Scott, Brent D. G. Page, Brian O. Patrick, Chris Orvig · 2008 · Dalton Transactions
93. 3,5-Disubstituted-4-hydroxyphenyls Linked to 3-Hydroxy-2-methyl- 4(1H)-pyridinone: Potent Inhibitors of Lipid Peroxidation and Cell Toxicity
    David Bebbington, Nathaniel J. T. Monck, Suneel Gaur, Alan M. Palmer, Karen R. Benwell, Victoria L. Harvey, Craig S. Malcolm, Richard H. P. Porter · 2000 · Journal of Medicinal Chemistry
94. Wilson's Disease
    Jonathan D. Glass · 1990 · Archives of Neurology
95. The chemical form of mitochondrial iron in Friedreich’s ataxia
    Popescu, Bogdan F.Gh., Pickering, Ingrid J., George, Graham N., Nichol, Helen · 2007 · Journal of Inorganic Biochemistry
96. Assay To Screen for Molecules That Associate with Alzheimer's Related β-Amyloid Fibrils
    Petra Inbar, Mahealani R. Bautista, Stacy A. Takayama, Jerry Yang · 2008 · Analytical Chemistry
97. Functional dissection ofdrosophila capricious: its novel roles in neuronal pathfinding and selective synapse formation
    Hiroki Taniguchi, Emiko Shishido, Masatoshi Takeichi, Akinao Nose · 2000 · Journal of Neurobiology
98. Partition coefficients of the iron(III) complexes of pyridoxal isonicotinoyl hydrazone and its analogs and the correlation to iron chelation efficacy
    John T. Edward, Prem Ponka, Des Raymond Richardson · 1995 · BioMetals
99. Future Chelation Monotherapy and Combination Therapy Strategies in Thalassemia and Other Conditions. Comparison of Deferiprone, Deferoxamine, ICL670, GT56-252, L1NAll and Starch Deferoxamine Polymers
    George J. Kontoghiorghes · 2006 · Hemoglobin
100. Synthesis of feralex a novel aluminum/iron chelating compound
     Theo P.A. Kruck, Timothy E. Burrow · 2002 · Journal of Inorganic Biochemistry
101. Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Aβ fibril formation
     Seong Rim Byeon, Ji Hoon Lee, Ji‐Hoon Sohn, Dong Chan Kim, Kye Jung Shin, Kyung Ho Yoo, Inhee Mook‐Jung, Won Koo Lee, Dong Jin Kim · 2006 · Bioorganic & Medicinal Chemistry Letters
102. Preparation of New Bis(8‐aminoquinoline) Ligands and Comparison with Bis(8‐hydroxyquinoline) Ligands on Their Ability to Chelate CuII and ZnII
     Céline Deraeve, Alexandrine Maraval, Laure Vendier, Vanessa Faugeroux, Marguerite Pitié, Bernard Meunier · 2008 · European Journal of Inorganic Chemistry
103. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
     Moussa B. H. Youdim, Edna Grünblatt, Silvia A. Mandel · 2006 · Journal of Neural Transmission
104. Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer’s disease
     Laura Bica, Peter John Crouch, Roberto Cappai, Anthony Robert White · 2008 · Molecular BioSystems
105. Pyridoxal isonicotinoyl hydrazone and analogues
     Des Raymond Richardson, Lucia M. Wis Vitolo, Erica Bakers, John M. Webb · 1989 · BioMetals
106. 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer’s disease. Its comparative effects with clioquinol on rat brain copper distribution
     Vincent Moret, Younès Laras, Nicolas Pietrancosta, Cédrik Garino, Gilles Quéléver, Amandine Rolland, B. Mallet, Jean-Chrétien Norreel, Jean‐Louis Kraus · 2006 · Bioorganic & Medicinal Chemistry Letters
107. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy
     Devanur Ld, Robert W. Evans, Patricia Evans, Robert C. Hider · 2007 · Biochemical Journal
108. Synthesis of Biphenyltrienes as Probes for β-Amyloid Plaques
     Zhi‐Ping Zhuang, Mei‐Ping Kung, Hank F. Kung · 2006 · Journal of Medicinal Chemistry
109. Effect of chronic chloroquine administration on iron loading in the liver and reticuloendothelial system and on oxidative responses by the alveolar macrophages
     Rachida Legssyer, Roberta J. Ward, Robert R. Crichton, Johan R. Boelaert · 1999 · Biochemical Pharmacology
110. Treatment of Lead Poisoning with Sodium Citrate
     Seymour S. Kety, T. V. Letonoff · 1941 · Experimental Biology and Medicine
111. RNAA for arsenic, cadmium, copper, and molybdenum in CNS tissues from subjects with age-related neurodegenerative diseases
     Lav Tandon, B. -F. Ni, X. X. Ding, William D. Ehmann, Edward J. Kasarskis, William R. Markesbery · 1994 · Journal of Radioanalytical and Nuclear Chemistry
112. Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone
     Jason D. Czachor, M. George Cherian, James D. Koropatnick · 2002 · Journal of Inorganic Biochemistry
113. Drug Therapy in Amyotrophic Lateral Sclerosis
     B. Jane Distad, Gregg D. Meekins, Lee Loung Liou, Michael D. Weiss, Gregory T. Carter, Robert G. Miller · 2008 · Physical Medicine and Rehabilitation Clinics of North America
114. Chloroquine Reduces Neuronal and Glial Iron Uptake
     Kenneth F. Swaiman, Valynda L. Machen · 1986 · Journal of Neurochemistry
115. Comparative iron binding studies of bis- and tris(3-hydroxy-2-methylpyrid-4-ones) and desferrioxamine
     Lyndon N. Sheppard, George J. Kontoghiorghes · 1991 · Inorganica Chimica Acta
116. Prodrug and covalent linker strategies for the solubilization of dual-Action antioxidants/Iron chelators
     David Bebbington, Claire E. Dawson, Suneel Gaur, John Spencer · 2002 · Bioorganic & Medicinal Chemistry Letters
117. Clioquinol
     Gandharva Padmanabhan, Ingrid Becue, James Barclay Smith · 1990 · Analytical profiles of drug substances
118. The use of conformation‐specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases
     S. Rutger Leliveld, Carsten Korth · 2007 · Journal of Neuroscience Research
119. Yttrium 90 ibritumomab tiuxetan (Zevalin®): A new bullet in the fight against malignant lymphoma?
     Bjoern Chapuy, Karin Hohloch, Lorenz H. P. Trümper · 2007 · Biotechnology Journal
120. Desferrithiocin Analogues and Nephrotoxicity
     Raymond J. Bergeron, Jan Wiegand, James S. McManis, Neelam Bharti, Shailendra Pratap Singh · 2008 · Journal of Medicinal Chemistry
121. Assessment of antimalarial effect of ICL670A on in vitro cultures of Plasmodium falciparum
     Carmen Goudeau, Mark Loyevsky, Olakunle O. Kassim, Victor R. Gordeuk, Hanspeter Nick · 2001 · British Journal of Haematology
122. Synthesis of Lipophilic 3-Hydroxy-2-methyl-4-pyridinone Derivatives
     G. Liu, Scott C. Miller, Fred W. Bruenger · 1995 · Synthetic Communications
123. Synthesis and Evaluation of Long-Acting D-Penicillamine Derivatives
     Milos S. Chvapil, Filip Kielar, František Liška, A. SILHANKOVA, Klaus Brendel · 2005 · Connective Tissue Research
124. Untitled work
     Waldvogel · 1999 · 10.1002/1531-8249(199907)46:1